The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Research reported in this publication included work performed in the Biostatistics Core supported by the NCI of the NIH under award number P30CA033572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
LakhaniSREllisIOSchnittSJ. World Health Organization Classification of Tumours of the Breast. 4th ed.Lyons, France: International Agency for Research on Cancer; 2012.
AllredDCAndersonSJPaikS. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen-receptor positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol2012;30:1268–1273.
FisherBDignamJWolmark. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet1999;353:1993–2000.
CarlsonRWAndersonBOBensingerW. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2010. Accessed March 20 2015. To view the most recent version of these guidelines visit NCCN.org.
MargoleseRGCecchiniRSJulianTB. Primary results, NRG Oncology/NSABP B-35: a clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIs undergoing lumpectomy plus radiation [abstract]. J Clin Oncol2015;33(Suppl):Abstract LBA 500.
Cuncins-HearnABoultMBabidgeW. National Breast Cancer Audit: ductal carcinoma in situ management in Australia and New Zealand. ANZ J Surg2007;77:64–68.
YenTWHuntKKMirzaNQ. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer2004;100:942–949.
NakhlisFLazarusLHouN. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b invasive carcinoma. J Am Coll Surg2005;201:688–694.
ZujewskiJAHarlanLCMorrellDM. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat2011;127:251–257.
NCCN Member Institutions. Available at: https://www.nccn.org/members/network.aspx. Accessed May 28 2015.
NCI-Designated Cancer Centers. Available at: cancer.gov/research/nci-role/cancer-centers. Accessed May 28 2015.
California Cancer Registry. Available at: http://ccrcal.org. Accessed December 21 2014.
RhoadsKFPatelMIMaYSchmidtLA. How do integrated health care systems address racial and ethnic disparities in colon cancer?J Clin Oncol2015;8:854–860.
North American Association of Central Cancer Registries. US Registries Certified in 2013 for 2010 Incidence Data. Available at: http://www.naaccr.org/Certification/USCert2010.aspx. Accessed May 24 2015.
YangJSchuppCWHarratiA. Developing an area-based socioeconomic measure from American Community Survey data. Fremont, CA: Cancer Prevention Institute of California; 2014. Available at: http://www.cpic.org/files/PDF/Research_Files/Reports/CPIC_ACS_SES_Index_Documentation_3-10-2014.pdf. Accessed July 25 2016.
YostKPerkinsCCohenR. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control2001;12:703–711.
Office of Statewide Health Planning and Development. Available at: http://www.oshpd.ca.gov/AboutUs.html. Accessed March 9 2015.
California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures for Hospitals. Available at: http://ccrcal.org/DSQC_Pubs/V1_2013_Online_Manual/index.htm. Accessed July 25 2015.
GradisharWJAndersonBOBalassanianR. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2015. Accessed March 20 2015. To view the most recent version of these guidelines visit: http://www.nccn.org.
WapnirILDignamJJFisherB. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NASBP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst2011;103:478–488.
YenTWKuererHMOttesenRA. Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. J Clin Oncol2007;25:3251–3258.
RutterCEParkHSKilleleaBKEvansSB. Growing use of mastectomy for ductal carcinoma-in-situ of the breast among young women in the United States. Ann Surg Oncol2015;22:2378–2386.
ShanjunLLaxminarayanR. Are physicians' prescribing decisions sensitive to drug prices? Evidence from a free-antibiotics program. Health Econ2015;24:158–174.
RibieCSargentDMooreM. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med2003;349:247–257.
BaileySRSapersteinAPennerAM. Race, color, and income inequality across the Americas. Demographic Research2014;31:735–756. Available at: http://www.demographic-research.org/volumes/vol31/24/31-24.pdf. Accessed July 25 2016.
MargoleseRGCecchiniRSJulianTB. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet2016;387:849–856.
HadjiP. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol2010;73:156–166.
MeguerditchianANStewartARoistacherJ. Claims data linked to hospital registry data enhance evaluation of the quality of care of breast cancer. J Surg Oncol2010;101:593–599.